You are here: Industry Insights > KemPharm

News List

KemPharm Appoints Tamara A. Seymour to Board of Directors firstwordpharma
August 19, 2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee
KemPharm Receives $10M Milestone Payment for FDA Approval of AZSTARYS™ americanpharmaceuticalreview
April 23, 2021
KemPharm, Inc. has announced receipt of a regulatory milestone payment of $10 million for the FDA approval of AZSTARYS™ in accordance with the recently amended definitive collaboration and license agreement with Commave Therapeutics, SA, an affiliate ...
KemPharm Receives $10M Milestone for FDA Approval of Azstarys contractpharma
April 23, 2021
KemPharm Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, has confirmed receipt of a regulatory milestone payment of $10 million for the FDA approval of Azstarys in accordance with the recently ...
KemPharm Announces FDA Approval of AZSTARYS for ADHD americanpharmaceuticalreview
March 08, 2021
KemPharm has announced the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA) AZSTARYS™ (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in ...
KemPharm Receives of Two Additional U.S. Patents americanpharmaceuticalreview
August 04, 2020
KemPharm announced the United States Patent and Trademark Office (USPTO) has recently issued two new patents to KemPharm governing methods of use and composition of matter for methylphenidate-based prodrugs.
KemPharm Submits KP415 NDA to FDA for ADHD americanpharmaceuticalreview
March 04, 2020
KemPharm has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its investigational product candidate, KP415, to the U.S. Food and Drug Administration (FDA).
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP) drugs
January 08, 2019
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has approved a......